Saturday 17 October 2026
Export HRTX’s income statement to Excel — free account
Heron Therapeutics, Inc.
HRTX Healthcare Biotechnology
Heron Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $154.9 million, up 7.36% from fiscal 2024. In the quarter to June 2026, revenue grew 1.25%, EPS fell 93.6%, free cash flow grew 78.8% and total debt fell 18.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
0.36
0.02
−5.26%
Follow HRTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 4 | 3 | 2 |
| 82.34% | 198.30% | 303.85% | 318.21% | ||
| (5.78%) | (8.26%) | (12.84%) | (14.06%) | ||
ROIC |
1.01% | (1.46%) | (6.17%) | (6.35%) | |
Return on Tangible Assets |
(8.89%) | (13.08%) | (20.56%) | (22.77%) | |
Average Days of Receivables |
190.73 | 211.09 | 202.69 | 216.26 | |
Free Cash Flow per Share |
(0.18) | (0.17) | (0.11) | (0.06) | |
Free Cash Flow |
(31.03) | (27.81) | (20.80) | (12.09) | |
Capital Expenditures |
(0.85) | (0.22) | (0.54) | (0.48) | |
| Other line items | |||||
Cash ROIC |
(14.78%) | (13.79%) | (10.64%) | (6.29%) | |
Accounts Receivable Turnover |
2.09 | 1.84 | 1.86 | 1.78 | |
Accounts Payable Turnover |
3.64 | 3.99 | 4.09 | 3.82 | |
Inventory Turnover |
0.70 | 0.57 | 0.58 | 0.55 | |
Average Days of Payables |
108.42 | 79.40 | 75.22 | 93.91 | |
Days of Inventory on Hand |
631.78 | 818.74 | 775.98 | 730.80 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
7.65% | 8.02% | 8.32% | 8.14% | |
Selling, General and Administrative Expense of Revenue |
65.24% | 66.92% | 69.74% | 69.12% | |
Share Based Compensation of Revenue |
6.74% | 6.67% | 7.17% | 7.40% | |
Operating CF/Net income |
2.22 | 1.37 | 0.65 | 0.34 | |
Depreciation/Fixed assets |
0.17 | 0.19 | 0.21 | 0.21 | |
Capex/Depreciation |
(0.38) | (0.09) | (0.22) | (0.20) | |
Revenue per Share |
0.91 | 0.93 | 0.79 | 0.79 | |
Operating CF per Share |
(0.18) | (0.17) | (0.11) | (0.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.00 |
Columns are period end dates